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In 2013, we proposed a novel bottom-up approach to bounding low-dose cancer risks that may result
from small exogenous exposures to chemicals that are always present in the body as a result of normal
biological processes. The approach utilizes the background cancer risk and the background (endogenous)
concentration of a cancer-related exposure biomarker in speciﬁc target tissues. After allowing for sta-
tistical uncertainty in these two parameters, the ratio of the background risk to background exposure
provides a conservative slope factor estimate that can be utilized to bound the added risk that may be
associated with incremental exogenous exposures. Our original bottom-up estimates were markedly
smaller than those obtained previously by the US Environmental Protection Agency (USEPA) with a
conventional top-down approach to modeling nasopharyngeal cancer and leukemia mortality data from
a US worker cohort. Herein we provide updated bottom-up estimates of risk for these two cancers that
are smaller still, and rely upon more robust estimates of endogenous and exogenous formaldehyde-DNA
adducts in monkeys and a more robust estimate of the DNA adduct elimination half-life in rats, both
obtained very recently. We also re-examine the worker mortality data used by USEPA in developing its
estimate of human leukemia incidence from lifetime exposure to 1 ppm airborne formaldehyde. Finally,
we compare a new bottom-up slope estimate of the risk of rat nasal cancer with conventional top-down
estimates obtained with empirical dose-response modeling of rat nasal cancer bioassay data.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2013, we proposed a novel bottom-up approach to bounding
the low-dose human cancer risks that may arise from small exog-
enous exposures to chemicals that are always present in the body
as a result of normal biological processes such as metabolism (Starr
and Swenberg, 2013). This approach utilizes two parameters: 1) the
background cancer risk (P0) in a speciﬁc target tissue, and 2) the
background (endogenous) concentration (C0) of a cancer-related
exposure biomarker, such as a speciﬁc DNA adduct, measured in
the same tissue. After adjusting appropriately for statistical un-
certainty in these parameters by replacing the central, i.e.,
maximum likelihood, estimates of P0 and C0 with theirtal Sciences and Engineering,
Hall, CB #7431, Chapel Hill,
rr), jswenber@email.unc.edu
Inc. This is an open access article ucorresponding upper (P0U) and lower (C0L) conﬁdence bounds, the
ratio P0U/C0L provides a conservative cancer risk slope factor esti-
mate that can be utilized to bound the added risk that may be
associated with an incremental steady-state exogenous exposure
(Cxss). The approach assumes that this bound on added risk (ARU) is
predominantly linear near C0 and given by the equation:
ARU ¼ ðP0U=C0LÞ$Cxss:
Because the bottom-up approach makes an implicit assumption
that all of the background cancer risk P0 is attributable to the
background endogenous exposure C0, the resulting bound on
added risk is “worst case” in that regard.
Strengths of our bottom-up approach are that it 1) is consistent
with the “additivity to background” concept; 2) yields upper-bound
risk estimates that are linear, and 3) requires only information on
background risk, background (endogenous) exposure, and the
additional steady-state exogenous exposure in order to be imple-
mented. The bottom-up approach thus provides an independentnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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typical top-down approach of ﬁtting dose-response models to
high-dose human or laboratory animal cancer data. The key
biotechnological advance that underpins this novel approach is the
extraordinary ability to distinguish between and separately quan-
tify target tissue exposures that arise from unlabeled internal
(endogenous) sources and dual stable isotope-labeled external
(exogenous) sources, even when the endogenous exposure is sub-
stantially larger and more uncertain than the steady-state exoge-
nous exposure of interest (c.f., Lu et al., 2010, 2012; Moeller et al.,
2011; Swenberg et al., 2011, 2013; Yu et al., 2015).
When we introduced the bottom-up approach (Starr and
Swenberg, 2013), we illustrated its application with an analysis of
potential human cancer risks posed by inhalation exposures to
formaldehyde. We used recent US national mortality statistics for
nasopharyngeal cancer, Hodgkin lymphoma, and leukemia for
estimates of P0 and P0U. We used short-term measurements of
speciﬁc formaldehyde-DNA adducts (N2-hydroxymethyl-dG
(N2-HOMe-dG) adducts) in the presumptive target tissues for these
cancers (nasal respiratory epithelium, blood, and bone marrow,
respectively) in monkeys (Moeller et al., 2011), a surrogate species
for humans. We assumed that the measured endogenous adduct
concentrations were at steady-state, since endogenous exposure is
continuous and ongoing at all times. We then extrapolated from
time-speciﬁc exogenous adduct concentrations (measured in
monkeys after 2 ppm formaldehyde exposure for 6 h on two
consecutive days) to the steady-state values (Cxss) that would be
expected to arise from continuous 24/7 exposure using a simple
one compartment pharmacokinetic model of DNA adduct forma-
tion and elimination. The 63 h elimination half-life that we utilized
in the kinetic model had been derived previously from limited
short term data obtained with rats (Swenberg et al., 2013).
Our original bottom-up estimates of added risk were markedly
smaller than those that had been obtained by the US Environmental
Protection Agency (USEPA, 2010) with a conventional top-down
approach that utilized data from occupational cohort mortality
studies of formaldehyde-exposed workers (Hauptmann et al.,
2004; Beane-Freeman et al., 2009). For nasopharyngeal cancer
mortality, our bottom-up bound on added risk from lifetime
continuous exposure to 1 ppm formaldehyde (0.038  102) was
nearly 29-fold lower than USEPA's “plausible” upper bound esti-
mate for nasopharyngeal cancer incidence (1.1  102), while our
bottom-up bound for the added risk of developing leukemia
(<3.9  106) from the same lifetime exposure was more than
14,000-fold lower than the corresponding USEPA estimate for
leukemia incidence (5.7  102).
Hereinwe provide updated estimates of added risk for leukemia
and nasopharyngeal cancer using the same bottom-up approach.
The new estimates rely upon more robust estimates of tissue-
speciﬁc endogenous and exogenous formaldehyde-DNA adducts
in monkeys and a more robust estimate of the DNA adduct elimi-
nation half-life in rats, both of which were obtained very recently
by Yu et al. (2015).We also examinemore closely the data that were
used by USEPA (2010) in developing its estimate of leukemia inci-
dence from lifetime exposure to 1 ppm airborne formaldehyde.
Finally, we compare a newly derived bottom-up added risk es-
timate for rat nasal cancer incidence with a conventional top-down
estimate that we obtained with empirical dose-response modeling
of pooled nasal cavity squamous cell carcinoma data that were
taken from two formaldehyde carcinogenicity bioassays (Kerns
et al., 1983; Monticello et al., 1996) and selected historical control
groups from National Toxicology Program (NTP) inhalation bio-
assays (Subramaniam et al., 2007). These data provide the very best
currently available information, in terms of the range of airborne
formaldehyde concentrations studied and the accuracy andprecision of both exposure concentrations and tumor incidence,
that can be used in evaluating the performance of the bottom-up
and top-down extrapolation approaches to bounding potential
cancer risks from low level airborne formaldehyde exposures.
2. Materials and methods
2.1. Human cancer risk estimates
For background lifetime risk of death from nasopharyngeal
cancer, we employed the same risk estimate that we used previ-
ously in Starr and Swenberg (2013), namely, 7.25 104, which was
taken from USEPA's 2 June 2010 draft formaldehyde assessment
(see Table C-1, p C-3 and Section 5.2.2 in USEPA (2010)). The
2010e2012 all races background lifetime risk of developing leu-
kemia (ICD-10 codes C91-C95) absent exogenous formaldehyde
exposure (1.47  102) was taken from Table 13.20 of the SEER
Cancer Statistics Review 1975e2012 (Howlader et al., 2015). This
value is about 13% higher than the previous SEER estimate
(1.30  102) for the period 2005e2007, which we employed
previously in Starr and Swenberg (2013). Because these background
lifetime risk estimates apply to the entire US population, their
uncertainty is extremely small, i.e., P0 and P0U are practically
identical, differing by a few percent at most, and we have therefore
utilized P0 in all of our bottom-up calculations of human risk.
Also, stratiﬁed leukemia (ICD-8 codes 204-207) mortality data
were taken from the National Cancer Institute (NCI) occupational
cohort mortality study of formaldehyde-exposed workers (Beane-
Freeman et al., 2009). Observed and expected numbers of leuke-
mia deaths in four cumulative formaldehyde exposure strata (un-
exposed, >0 e <1.5 ppm-yr, 1.5e5.5 ppm-yr, > 5.5 ppm-yr) were
utilized herein to consider whether top-down dose-response
modeling and extrapolation of predicted risks could be justiﬁed
scientiﬁcally. These data and corresponding Standardized Mortality
Ratios (SMRs) for the same strata were kindly provided by Dr.
Kenneth A. Mundt, Ramboll ENVIRON International Corporation
(personal communication). Dr. Mundt also provided us with
stratum-speciﬁc mean cumulative exposure values for these strata
that were utilized in top-down Poisson regression dose-response
modeling of leukemia mortality in the NCI cohort (Beane-Freeman
et al., 2009). All modeling calculations were implemented in
Microsoft Excel 2007. Four polynomial dose-response models
(constant, linear with unit intercept, linear, and quadratic) were ﬁt
by maximum likelihood to the stratiﬁed mortality data using the
maximum likelihood method implemented with the Excel Solver
optimization routine.
2.2. Rat nasal cancer risk estimates
The background lifetime risk estimate for nasal squamous cell
carcinoma (SCC) in Fischer 344 rats (1/4949) was taken from
Subramaniam et al. (2007), who combined nasal SCC incidence in
the concurrent control groups from two formaldehyde inhalation
bioassays (Kerns et al., 1983; Monticello et al., 1996) with that in
several historical control groups from a series of National Toxi-
cology Program (NTP) inhalation bioassays (see Table 1 in
Subramaniam et al. (2007) and related discussion for details). We
also utilized the SCC dose-response data from Kerns et al. (1983)
and Monticello et al. (1996) as combined by Subramaniam et al.
(2007) in our top-down dose-response modeling of tumor inci-
dence versus estimated steady-state formaldehyde-DNA adduct
concentrations in rat nasal respiratory epithelium. A Weibull
model, modiﬁed to allow for the possibility of a linear term in
addition to the model's standard power law dose-dependence, was
ﬁt to the rat tumor data up to and including that for the 10 ppm
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Microsoft Excel 2007 Solver optimization routine, while a multi-
stage model was ﬁt to the same data using the Global 82 com-
puter program (Howe and Crump, 1986).
2.3. Endogenous and exogenous formaldehyde-DNA adducts
Species- and tissue-speciﬁc data for endogenous formaldehyde-
DNA adducts (N2-HOMe-dG mono adducts) in air control monkeys
(cynomolgus macaques) (n ¼ 4 for nasal tissue; n ¼ 10 for scraped
bone marrow), and air control Fischer 344 rats (n ¼ 8 for nasal
tissue), were taken from Yu et al. (2015). The air control monkeys
were whole body-exposed to ﬁltered air for 6 h on 2 consecutive
days. The air control rats received 28 consecutive days of 6 h per
day nose-only exposure to ﬁltered air.
Yu et al. (2015) collected monkey nasal tissue samples from 5
distinct areas of the nasal cavity (dorsal mucosa, nasapharynx,
septum, anterior maxillary turbinate, and posterior maxillary
turbinate). All possible (n ¼ 10) paired sample t-tests were con-
ducted to determine if there were any signiﬁcant differences in
endogenous adduct concentrations with nasal cavity location. No
such differences were found, even without adjusting for the mul-
tiple comparisons, so the area-speciﬁc values were combined into a
nasal cavity mean value for each monkey, and these means were
then used to calculate a single overall grand mean value and
standard error of estimate.
Tissue-speciﬁc concentrations of stable isotope-labeled exoge-
nous formaldehyde-DNA adducts in the nasal tissues of exposed
monkeys measured following 6 h exposures to 6 ppm formalde-
hyde on two consecutive days were also taken from Yu et al. (2015).
However, these adducts were not detected in any monkey bone
marrow sample (average sample size ¼ 22.78 nMol dG (Dr. Rui Yu,
personal communication)). We therefore utilized Yu et al.'s
analytical method detection limit for these adducts on column
(0.5 amol) to specify an upper bound on how many exogenous
adducts could be present but still remain undetected in the average
amount of dG present in scraped bone marrow samples. Yu et al.'s
0.5 amol detection limit on column thus corresponds to 0.5 1018/
22.78  109, or 0.000219 adducts per 107 dG.
Finally, data for dual stable isotope-labeled exogenous
formaldehyde-DNA adducts in rat nasal tissue following single 6 h
exposures to airborne formaldehyde concentrations 0.7, 2.0, 5.8, or
9.1 ppm were taken from Table 1 of Lu et al. (2010) for use in top-
down dose-response modeling of the rat nasal tumor incidence
data. The Lu et al. (2010) values for 0.7 and 2 ppm formaldehyde
were used directly. The Lu et al. (2010) values for 5.8 and 9.1 ppm
formaldehyde were extrapolated upward linearly to the closest
bioassay formaldehyde concentrations reported in Table 1 of
Subramaniam et al. (2007), namely, 6.01 and 9.93 ppm.
3. Results
3.1. Bottom-up nasopharyngeal cancer and leukemia mortality risk
estimates
Table 1 summarizes the elements involved in using the bottom-
up approach to predict potential human upper bound risks of death
from nasopharyngeal cancer and the development of leukemia that
might arise from continuous lifetime exposure to 1 ppm formal-
dehyde. Both of these bottom-up risk estimates are reduced (by
about 1.4-fold for nasopharyngeal cancer and 3.1-fold for leukemia)
relative to the estimates presented previously in Starr and
Swenberg (2013). The 1.4-fold reduction in nasopharyngeal can-
cer mortality risk is due primarily to a 1.7-fold increase in the es-
timate of C0L in monkey nasal tissues, which decreases the bottom-up slope estimate P0/C0L. This increase in the estimate of C0L is due
at least in part to the fact that the endogenous adduct concentration
C0 in monkey tissue is more tightly estimated with the new data
from Yu et al. (2015).
The 3.1-fold reduction in the bottom-up bound on leukemia risk
is due primarily to the increased sensitivity of the analytical
method employed by Yu et al. (2015), who now have an on-column
detection limit of 0.5 attoMol, 40-fold lower than the previous
value (20 attoMol) reported by Moeller et al. (2011). This reduction
is counterbalanced in part by a decrease in the quantity of DNA
collected per sample, and an approximately 60% decrease in the
estimates of C0 and C0L in scraped bone marrow relative the pre-
vious estimates reported by Moeller et al. (2011).
Use of the new DNA adduct data from Yu et al. (2015) enhanced
the contrast between the bottom-up risk estimates and USEPA's
top-down estimates. The bottom-up estimate of nasopharyngeal
cancer mortality risk from lifetime exposure to 1 ppm formalde-
hyde is now over 40-fold lower than the USEPA (2010) estimate of
1.1%, while the corresponding bottom-up estimate of developing
leukemia is now more than 45,000-fold lower than the USEPA
(2010) estimate of 5.7%. These profound contrasts call the scienti-
ﬁc credibility of the Agency's estimates into serious question,
especially for the lifetime risk of developing leukemia.3.2. Top-down dose-response analyses of human leukemia
mortality
Table 2 and Fig. 1 provide the data utilized in our top-down
dose-response modeling of human leukemia mortality. It is
readily apparent that 1) the 50% deﬁcit in leukemia mortality in the
unexposed stratum is nearly statistically signiﬁcant (95% conﬁ-
dence interval¼ (0.24, 1.04), and 2) there is little, if any, evidence of
a positive dose-response relationship between leukemia mortality
and cumulative formaldehyde exposure amongst exposed person-
years (SMR ¼ 0.96, 0.96, 1.27 for the three strata with nonzero
cumulative exposure).
Table 3 and Fig.1 summarize results from our Poisson regression
modeling efforts. The c2 Goodness of Fit test p-values, all greater
than p ¼ 0.05, indicate that each of the four polynomial models
provided adequate ﬁts to the data. However, the unconstrained
linear model (Fig. 1b), failed to provide a signiﬁcantly better ﬁt to
the data than did the pure intercept model (Fig. 1a) (c2 likelihood
ratio test p-value ¼ 0.089, 1 degree of freedom (df)), and the
quadratic model (Fig.1c) failed to provide a signiﬁcantly better ﬁt to
the data than did the linear model (c2 likelihood ratio test p-
value ¼ 0.760, 1 df) or the pure intercept model (c2 likelihood ratio
test p-value ¼ 0.255, 2 df). In other words, the pure intercept
model, a simple horizontal (zero slope) straight line, provided an
entirely satisfactory description of the data, consistent with the lack
of evidence for a positive association between leukemia mortality
and cumulative formaldehyde exposure in this cohort. These re-
sults are in complete agreement with the nonsigniﬁcant log-linear
trend test statistics reported previously by Beane-Freeman et al.
(2009) for their unstratiﬁed analysis of the NCI leukemia mortal-
ity data, namely, p-value ¼ 0.08 using all person-years, and p-
value ¼ 0.12 using only exposed person-years.
In summary, our stratiﬁed dose-response analyses conﬁrm the
previous ﬁndings of Beane-Freeman et al. (2009) that there is no
substantive evidence of a positive dose-response relationship be-
tween leukemia mortality and cumulative formaldehyde exposure
in the NCI cohort. In such circumstances, top-down extrapolations
from the leukemia mortality observed in this cohort to potential
risks arising from far lower levels of chronic environmental form-
aldehyde exposures are simply not scientiﬁcally justiﬁed.
Table 1
Estimated lifetime risks of death from nasopharyngeal cancer and development of leukemia from continuous lifetime inhalation exposure to 1 ppm formaldehyde, as re-
estimated with the bottom-up approach using more robust input data and, alternatively, by USEPA using top-down linear extrapolation from epidemiologic data (as taken
from Table 6-3, pp 6.41 e 6.42, of the Agency's draft toxicological assessment (USEPA, 2010)). For comparison, previous bottom-up estimates of slope, steady-state exogenous
formaldehyde-DNA adduct concentrations, and risk from Starr and Swenberg (2013) are shown in parentheses. All formaldehyde-dG adduct concentrations are expressed as
the number of adducts per 107 dG in cynomolgus monkey nasal tissues or scraped bone marrow.
Endpoint Background
Risk P0
C0 ± seC0L B-U slopea
P0/C0L
Cx30 @ 6 ppm
Cxss @ 6 ppm
Cxss @ 1 ppm Bottom-upa
ARU @ 1 ppm
EPA UCL95
Risk @ 1 ppm
Nasopharyngeal Cancer 7.25  104 3.84 ± 0.18
3.55
(3.44  104)
2.04  104
0.363 ± 0.015
7.935 ± 0.328
(1.10)
1.32
(3.80  104)
2.69  104
1.1  102
Leukemia 1.47  102 10.18 ± 0.43
9.48
(0.85  103)
1.55  103
<2.19  104
<4.79  103
(<4.56  103)
<7.98  104
(<3.90  106)
<1.24  106
5.7  102
a For human background risks, the central (P0) and upper bound (P0U) estimates are nearly identical due to the very large sample size (the entire US population), so bottom-
up slope and added risk estimates utilize P0, not P0U.
Table 2
Observed and expected deaths and SMRs for stratiﬁed leukemia mortality data (ICD codes 204-207) versus stratum-speciﬁc mean cumulative exposure in the NCI cohort with
followup through 2004, as constructed by Dr. Kenneth Mundt, Ramboll ENVIRON Corporation (personal communication).
Exposure stratum Exposure, ppm-yearsa Observed deaths Expected deathsb SMRb 95% conﬁdence interval
0 0 7 14.1 0.50 (0.24, 1.04)
>0 to <1.5 0.342 63 65.5 0.96 (0.75, 1.23)
1.5 to < 5.5 2.963 23 23.9 0.96 (0.64, 1.45)
>5.5 16.656 30 23.7 1.27 (0.89, 1.81)
a Mean cumulative exposures within each stratum were calculated using a 2-year lag.
b Expected deaths and the SMR were calculated using SEER CanQues US mortality rates for 1970e2009.
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Based on the cumulative binomial distribution, the estimated
background incidence of rat nasal cancer taken from Subramaniam
et al. (2007), namely, P0¼ 1/4949¼ 2.021 104, has an upper 95%
conﬁdence bound (P0U) of 9.582  104, i.e., nearly 5-fold higher
than P0. Furthermore, the number of endogenous N2-HOMe-dG
adducts in rat nasal tissue taken from Yu et al. (2015), namely,
C0 ¼ 2.84 per 107 dG, has a lower 95% conﬁdence bound of
C0L¼ 2.84e1.645 0.54/√8¼ 2.53 per 107 dG. Thus, the bottom-up
bound on the added risk slope factor for rat nasal cancer is given by
P0U/C0L ¼ 3.793  104 per 107 dG. Table 4 presents the bottom-up
added risk estimates (ARU) for lifetime exposure of rats using the
standard chronic inhalation bioassay exposure regimen (6 h/day, 5
days/week) to selected airborne formaldehyde concentrations up to
2 ppm.3.4. Top-down dose-response analyses of rat nasal cancer data
Table 5 summarizes the dose-response data utilized in our top-
downmodeling of rat nasal cancer. Column 1 provides the airborne
formaldehyde concentrations reported in Table 1 of Subramaniam
et al. (2007). Column 2 shows the number of exogenous N2-
HOMe-dG adducts present in rat nasal epithelium following a
single 6 h exposure to each of those airborne formaldehyde con-
centrations (Cx6) as reported by Lu et al. (2011) for 0., 0.7, and
2.0 ppm, or as extrapolated linearly upward to values for 6.01 and
9.93 ppm formaldehyde from the values Lu et al. (2011) reported for
5.8 and 9.1 ppm.
The exogenous formaldehyde-DNA adduct concentrations
following 6 h of exposure were converted to the steady-state
concentrations Cxss (shown in Column 3 of Table 5) that would
arise from chronic 6 h/day 5 day/week exposure using the 171 h
adduct elimination half-life (T1/2) reported by Yu et al. (2015) and
their one compartment pharmacokinetic model, which assumes
that the rate of adduct formation and clearance is constant
throughout life. This model implies the following mathematical
relationship between Cxss and Cx6:Cxss ¼ Cx6=ð1 expð  6=TÞÞ  ð6=24Þ  ð5=7Þ;
where T¼ T1/2/ln(2)¼ 246.7 h, andwhere themultiplicative factors
of (6/24) and (5/7) are included to account for the discontinuous
6 h/day 5 day/week bioassay exposure regimen. The total N2-
HOMe-dG steady-state adduct burden shown in column 4 of
Table 5 was obtained by summing these adjusted Cxss values and
the endogenous background adduct concentration C0 (2.84 per
107 dG), also taken from Yu et al. (2015).
Dose-response modeling results are presented in Table 6.
Goodness of ﬁt statistics for the modiﬁed Weibull and multistage
models were virtually identical (c2(2) ¼ 0.108 and 0.107, respec-
tively), and both model ﬁts were excellent (p ¼ 0.947 and 0.948,
respectively) and essentially indistinguishable from one another.
The maximum log-likelihood values for the two models (80.2370
and 80.2375, respectively) were also virtually identical.
Both of the ﬁtted models had a substantial intercept parameter
(a0), indicating that only a small fraction of the background cancer
risk (approximately 10%) was attributed by the ﬁtting process to the
endogenous rat nasal tissue adduct burden C0., with the balance of
the background risk being attributed to sources other than the
background adduct burden. In addition, the linear terms in both
models were driven to zero during the model optimization process.
In fact, apart from the intercept parameter a0, the only non-zero
dose coefﬁcients in the multistage model were for the ﬁfth (a5)
and sixth (a6) powers of dose, and the value of the power parameter
p for the modiﬁed Weibull model was equal to 5.86. These results
reﬂect the highly nonlinear dose-dependence of the rat nasal tu-
mor response. They are also entirely consistent with the top-down
dose-response modeling results we obtained with airborne form-
aldehyde concentration as the dose-metric (data not shown).
The last two rows of Table 6 present maximum likelihood esti-
mates of risk and the slope of the top-down dose-response models
at the three rat nasal tissue adduct concentrations (2.84, 3.39, and
4.25 adducts per 107 dG), corresponding to 0, 1, and 2 ppm airborne
formaldehyde, respectively. It is noteworthy that both of the ﬁtted
models predict risks at 2.84 (0 ppm) and 3.39 adducts per 107 dG
(1 ppm) that are actually smaller than the observed background
(a)
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Fig. 1. 1a-1c. Plots of Standardized Mortality Ratios for leukemia in the NCI cohort
stratiﬁed on cumulative formaldehyde exposure. Also shown are the best ﬁtting pure
intercept (1a), linear (1b), and quadratic (1c) dose-response models as estimated with
Poisson regression (see Tables 2 and 3 for additional information).
Table 3
Poisson regression model ﬁts to the stratiﬁed human leukemia mortality data
summarized in Table 1.
Model Parameters GOFa c2/df GOF p-value ln likelihood
b0 b0 0.963 5.658/3 0.129 322.699
1 þ b1 X b1 0.0150 4.054/3 0.256 323.982
b0 þ b1 X b0 0.869
b1 0.0248
2.859/2 0.239 324.145
b0 þ b1 X þ b2 X2 b0 0.847
b1 0.0567
b2 0.00188
2.831/1 0.092 324.192
a GOF: Goodness of Fit.
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exceed the observed background risk at or above 3.9 adducts per
107 dG, which is only 10% lower than the 4.25 adducts per 107 dG
that result from chronic exposure to 2 ppm formaldehyde.
All of the slopes of the top-down models shown in Table 6 are
smaller than our bottom-up slope central slope of estimate (P0/C0),
namely, (1/4949)/2.84 per 107 dG, or 7.11482  105 per 107 dG.
Furthermore, the top-down model slopes are substantially smaller
than our bottom-up upper bound slope (P0U/C0L), namely
3.79  104 per 107 dG, even at a total adduct burden of 4.25 per
107 dG (2 ppm). Ratios of our bottom-up upper bound slope to the
maximum likelihood slope estimate from the modiﬁed Weibull
(multistage) model are 57.0 (43.6) at 2.84  107 per dG (0 ppm),
24.2 (19.6) at 3.39 per 107 dG (1 ppm), and 8.1 (7.0) at 4.25 per
107 dG (2 ppm), respectively. Our bottom-up upper bound estimate
of the low-dose slope of the rat nasal cancer response thus exceeds
the top-down model slope estimates by nearly an order of
magnitude or more up to 2 ppm formaldehyde.
4. Discussion
4.1. Bottom-up human cancer risk estimates
Our updated bottom-up upper bound risk estimates for human
nasopharyngeal cancer and leukemia mortality rely on more robust
data for key input parameters, namely, extensive additional mea-
surements of endogenous and exogenous N2-hydroxymethyl-dG
adduct numbers in the relevant target tissues of a human surrogate
species, cynomolgus monkeys, as well as a signiﬁcantly improved
estimate of the half-life of these adducts obtained from male rat
nasal tissue data collected following repeated 6 h exposures to
2 ppm formaldehyde for up to 28 consecutive days (Yu et al., 2015).
However, at present, an assumption of cross-species equivalence of
1) tissue-speciﬁc formaldehyde-DNA adduct numbers, and 2) the
elimination half-life for these adducts is necessary if the available
nonhuman data are to be utilized in quantitative risk assessments
of human exposures to formaldehyde. This cross-species equiva-
lence assumption still needs to be validated and/or replaced with
measurements of formaldehyde-DNA adducts in human tissues,
and we are optimistic that such data will be obtained in the near
future.
In addition, it is important to note that use of the short-term
DNA adduct data to construct a dose metric suitable for lifetime
cancer risk extrapolation necessitates the assumption that
formaldehyde-DNA adduct formation and clearance, be it from
either endogenous or exogenous formaldehyde sources, occurs
throughout life at the same steady-state rate that we have inferred
from the short-term data via pharmacokinetic modeling. We
believe this is a reasonable assumption, but it has not yet been
validated and/or replaced with longer term measurements in hu-
man, subhuman primate, or rodent tissues. Fuller discussions of the
strengths, limitations, and relevance of short-term DNA adduct
data to cancer risk assessment can be found in Jarabek et al. (2009),
Himmelstein et al. (2009), Swenberg et al. (2011, 2013), and
Pottenger et al. (2014).
While our updated bottom-up risk estimates have served to
heighten themarked contrasts between our previous estimates and
the corresponding USEPA (2010) risk estimates, the changes from
our previous estimates, namely, a 1.4-fold reduction in nasopha-
ryngeal cancer mortality, and 3.15-fold reduction in leukemia
mortality, are not dramatic, with the larger difference for leukemia
mortality being due primarily to themarkedly lower detection limit
for the analytical method that is now being used to quantify
formaldehyde-DNA adduct numbers.
Is USEPA's leukemia upper bound slope factor estimate of 5.7%
Table 4
Bottom-up estimates of added risk of nasal cancer to rats exposed chronically to selected airborne formaldehyde concentrations for 6 h/day, 5 days/week.
Airborne concentration, ppm Cx6, adducts per 107 dG Cxss, adducts per 107 dG ARU, bottom-up
Bound on added riska
0 0 0 0
0.1 0.006 0.04 1.57  105
0.7 0.039 0.29 1.10  104
1.0 0.095 0.71 2.67  104
2.0 0.190 1.41 5.35  104
a ARU ¼ (P0U/C0L) x Cxss.
Table 5
Data for rat nasal tissue formaldehyde-DNA adducts and squamous cell carcinoma incidence that were utilized in top-down dose-response modeling.
Air concentration, ppm Cx6,a adducts per 107 dG Cxss,b adducts per 107 dG CTot,c adducts per 107 dG Squamous cell carcinoma incidenced
0 0 0 2.84 1/494
0.7 0.039 0.29 3.13 0/107
2.0 0.19 1.41 4.25 0/353
6.01 1.08 8.03 10.87 3/343
9.93 2.22 16.50 19.34 22/103
a Taken from Lu et al. (2011). The Cx6 values for 6.01 and 9.33 ppm were linearly extrapolated upward from the values for 5.8 and 9.1 ppm reported in Table 1 of Lu et al.
(2011).
b Quasi-steadystate values Cxss ¼ Cx6/(1-exp(-6/T)) x 6/24  5/7, where T ¼ T1/2/ln(2), and T1/2 ¼ 171 h.
c CTot ¼ Cxss þ C0.
d Pooled rat nasal tumor incidence taken from Subramaniam et al. (2007).
Table 6
Parameter estimates and ﬁtting statistics for modiﬁed Weibull and Multistage
models ﬁt by maximum likelihood (ML) to the rat nasal tumor data provided in
Table 5. Also shown are model-predicted risks and slopes for total formaldehyde-
DNA adduct burdens that result from chronic 6 h/day 5 day/week exposure to
exogenous formaldehyde concentrations of 0, 1, and 2 ppm. All formaldehyde-DNA
adduct concentrations are expressed as the number of adducts per 107 dG in rat
nasal respiratory epithelium.
Modiﬁed Weibull Model Multistage Model
a0 0.182190  103 a0 0.180526  103
a1 0 a1, a2, a3, a4, a7 0
ap 0.721100  108 a5 0.134914  107
P 5.84854 a6 0.389691  108
c2(2)
GOF p-value
0.108148
0.947362
0.107024
0.947895
Max Likelihood 80.2370 80.2375
ML Risk
@ 2.84 (0 ppm)
@ 3.39 (1 ppm)
@ 4.25 (2 ppm)
1.84973  104
1.91269  104
2.14807  104
1.85046  104
1.92462  104
2.22173  104
ML Slope
@ 2.84 (0 ppm)
@ 3.39 (1 ppm)
@ 4.25 (2 ppm)
6.65112  106
1.56911  105
4.69589  105
8.70653  106
1.93734  105
5.44163  105
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estimate was constructed using the NCI cohort data described by
Beane-Freeman et al. (2009), but that study reported no statistically
signiﬁcant association between leukemia mortality and workers'
cumulative formaldehyde exposure, with non-signiﬁcant trend
tests of mortality versus cumulative exposure using all person-
years (p ¼ 0.08) or only exposed person-years (p ¼ 0.12). Our
Poisson regression analyses of stratiﬁed data from the NCI cohort
(see Table 3 and Fig. 1) conﬁrm the absence of any signiﬁcant trend
in leukemia mortality with cumulative exposure. Indeed, as noted
earlier, linear and quadratic models of leukemia mortality versus
cumulative exposure failed to improve signiﬁcantly upon the ﬁt of a
pure intercept model that implies no relationship whatsoever be-
tween leukemia risk and cumulative formaldehyde exposure. To us,
it seems therefore to be altogether inappropriate to utilize top-
down dose-response modeling, as USEPA (2010) has done, toestimate low-dose leukemia risks as a function of cumulative
formaldehyde exposurewhen there is no substantive evidence for a
positive dose-response relationship between leukemia risk and
cumulative formaldehyde exposure. Simply put, there is no dose-
response to be modeled.
Furthermore, consideration needs to be given to the fact that
whole-body exposure of monkeys to 6 ppm airborne formaldehyde
for 6 h on two consecutive days failed to produce detectable
exogenous formaldehyde-DNA adducts in bone marrow. This is
compelling evidence that little, if any, inhaled exogenous formal-
dehyde reaches the bone marrow. There is thus no reason to expect
an increase in leukemia mortality from exogenous formaldehyde
exposure, even in the highest cumulative exposure stratum
(>5.5 ppm-years) of the NCI cohort, for which the average cumu-
lative exposure was 16.656 ppm-years (see Table 2). This value
corresponds to an average lifetime continuous airborne formalde-
hyde concentration of approximately 0.1 ppm (assuming aworkday
inhalation volume of 10 m3 out of a full 24 h inhalation volume of
20 m3) and an 80 year lifespan). This implies an upper limit on the
corresponding steady-state exogenous N2-hydroxymethyl-dG
adduct concentration Cxss of at most 7.98 105 per 107 dG in bone
marrow (7.98  104 per 107 dG per ppm  0.1 ppm). Thus, the
steady-state exogenous adduct burden in bone marrow could only
be about 0.78 105 of the endogenous adduct burden (7.98 105
per 107 dG/10.18 per 107 dG). It is difﬁcult to imagine how an in-
crease in the adduct burden from C0 to 1.0000078 C0, could cause a
greater than doubling of the SMR for leukemia, from 0.50 in un-
exposed workers to 1.27 in the most highly exposed workers (see
SMR leukemia data provided in Table 2). Such a result is simply not
credible.4.2. Regulatory agency concerns with the bottom-up approach
Since our initial publication describing the bottom-up approach
to human health risk assessment (Starr and Swenberg, 2013), there
have been numerous opportunities to present and discuss the
approach with regulators and the scientiﬁc community. We have
met privately with USEPA staff on three separate occasions to
describe the approach in detail and discuss the Agency's concerns
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Fig. 2. Plots of best-ﬁtting multistage andWeibull dose-response models (green curve)
for rat nasal cancer. Also shown are the bottom-up upper bound on added risk (red
line) and a depiction of the USEPA and Crump et al. (2014) speculative hypothesis (blue
curve) that the “true” dose-response curve is highly nonlinear below, at, and above the
endogenous background level of exposure (C0). Nasal tumor incidence data for 0, 0.7,
and 2.0 ppm formaldehyde are indicated by red squares. Observed background risk
denoted by P0.
T.B. Starr, J.A. Swenberg / Regulatory Toxicology and Pharmacology 77 (2016) 167e174 173about it. In collaboration with Dr. Robinan Gentry, we made a case
study presentation that included an illustration of how the bottom-
up approach could be applied to formaldehyde at an Alliance for
Risk Assessment workshop (Gentry et al., 2013). In addition, one of
us (TBS) and Dr. Kenny S. Crump made invited point-counterpoint
presentations on the bottom-up approach at a 2014 USEPA-
sponsored “State-of-the-Science Workshop to Discuss Issues Rele-
vant for Assessing the Health Hazards of Formaldehyde Inhalation”.
Finally, the substance of these latter two presentationswas reprised
in an exchange of letters to the editor of Regulatory Toxicology and
Pharmacology (Crump et al., 2014; Starr and Swenberg, 2014).
In essence, USEPA and Crump et al. (2014) have rejected the
bottom-up approach because it is linear, claiming that it is “highly
plausible” for the dose-response relationship between cancer risk
and the steady state target tissue DNA adduct concentration to be
highly sublinear even below the endogenous level C0, and claiming
further that such sublinearity forces the slope of the dose-response
relationship to exceed our bottom-up estimate (P0U/C0L) at all total
DNA adduct concentrations equal to or greater than C0.
These claims have no merit. First, there are no data regarding
cancer risks below C0, so any statements regarding the shape of the
dose-response relationship below C0 must be purely speculative.
Indeed, the dose-response relationship below C0 cannot even be
investigated, because the endogenous DNA adducts that comprise
C0 are always present, even when there is no exogenous exposure.
Furthermore, our bottom-up approach to bounding the cancer risk
at low doses includes no assumptions whatsoever regarding the
shape of the dose-response curve below C0. Instead, it conserva-
tively assumes only that 1) the upper bound on added risk at and
slightly above C0 is approximately linear, and that 2) all of the
background risk P0 might plausibly be attributable to the endoge-
nous background exposure C0.
As we noted in our response to Crump et al. (2014), one can
always posit an alternative hypothetical dose-response relationship
that exceeds any given empirically-derived upper conﬁdence
bound on extrapolated risk, including those that result from the
standard top-down approach to cancer risk assessment that has
been the common practice for many years (Starr and Swenberg,
2014). This should not be surprising because the values and
coverage properties of conﬁdence bounds on extrapolated risk
depend critically on the assumed dose-response relationship from
which these bounds are derived. If the assumed relationship is
changed, either qualitatively (different model type) or quantita-
tively (different parameter values), then the conﬁdence bounds will
change with it, and there are few “theoretical” constraints on the
shape of potential dose-response relationships save positivity,
continuity, differentiability and a ﬁnite (possibly zero) slope at zero
dose. Other regulatory agency constraints such as monotonicity
(precluding hormesis), low-dose linearity, and/or restriction of the
possibilities to a small number of “acceptable” empirical dose-
response relationships, e.g., the Weibull and multistage dose-
response models, may also be imposed.
What is surprising to us is that the USEPA and Crump et al.
(2014), who have been long-time proponents of low-dose line-
arity as a key constraint on the shape of the dose-response rela-
tionship, have chosen instead to now embrace the completely
antithetical position of predominant low-dose nonlinearity
without any supporting evidence. Therefore, the critical question is
this: what can be meaningfully inferred about potential cancer
risks at and above the endogenous background exposure level C0
from the limited tumor data that are available? To answer this
question, we chose the best available formaldehyde carcinogenicity
data set, namely, the pooled nasal tumor data for rats exposed
chronically to airborne formaldehyde in two carcinogenicity
bioassays.4.3. Bottom-up and top-down risk estimates for rat nasal cancer
When we incorporated endogenous and exogenous formal-
dehyde adduct data into the standard top-down risk assessment
approach and computed maximum likelihood estimates of low-
dose nasal cancer risk in chronically exposed rats using a
modiﬁed Weibull or the multistage model, we obtained results
very different from those shown in Fig. 1 of Crump et al. (2014),
where the hypothetical “true” sublinear dose-response relation-
ship passes directly through the background risk (P0) with a
slope at C0 and all higher exposure levels that appears to be
much greater than our bottom-up bound on the slope, the ratio
P0U/C0L.
As shown in our Table 6 and Fig. 2, both models (green curve)
are nonlinear and concave upward even when they are extrapo-
lated below C0, but they are nevertheless extremely ﬂat not only
below C0 but also for exposures that are substantially greater than
C0. Furthermore, the Weibull and multistage models both under-
predict the observed nasal cancer risk at C0, with most of the
observed background risk, approximately 90% of it, being attributed
by the models to sources other than the endogenous N2-hydrox-
ymethyl-dG adducts that are always present in rat nasal tissues.
This is reﬂected clearly in the substantial intercept parameters (a0)
of both models as shown in Table 6.
Fig. 2 and Table 6 also show clearly that our bottom-up bound on
risk (red line) exceeds, by a substantial margin, the ﬁtted Weibull
and multistage model risk estimates (green curve) up to and well
beyond the 4.25 total formaldehyde-dG adducts per 107 dG that
result from chronic 6 h/day 5 day/week inhalation exposure to
2 ppm formaldehyde. Fig. 2 and the results presented in Table 6 also
show that the bottom-up bound on the slope of nasal cancer risk
(slope of the red line in Fig. 2) is greater, bymore than a 57-fold (43-
fold) factor, than the slope of the Weibull (multistage) model at C0.
In addition, the bottom-up bound on the slope of predicted risk
continues to exceed by substantial margins the slopes of the Wei-
bull and multistage models at total formaldehyde-DNA adduct
burdens up to and including 4.25 per 107 dG (2 ppm). The rat nasal
tumor data, our bottom-up bounds on predicted risk and its slope,
and the predicted risks from the ﬁtted top-down dose-response
models thus contradict completely the groundless speculations of
Crump et al. (2014).
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We recognized from the outset that our bottom-up approach to
bounding low-dose human cancer risks would likely not apply at
exogenous exposures sufﬁciently high to induce nonlinear pro-
cesses that amplify the carcinogenic response, such as saturation of
metabolic pathways, cytotoxicity and tissue damage, and acceler-
ated regenerative cell proliferation. With formaldehyde, such pro-
cesses have been demonstrated to occur only at airborne
concentrations greater than 2 ppm (Monticello et al., 1996). We
therefore expect the bottom-up approach to provide valid bound-
ing estimates of added risk from exposure to all airborne formal-
dehyde concentrations up to and including 2 ppm. The bottom-up
approach may not always prove useful, but for cases where there is
a substantial endogenous exposure in potential target tissues and
little or no empirical evidence of a positive dose-response at low
exogenous exposure levels, we are conﬁdent that this approach
provides a robust and useful “reality check” on the typical top-
down risk extrapolations from high-dose tumor data that are
employed routinely in quantitative risk assessments.
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